RGEN Repligen Corporation
RGEN Repligen Corporation
Healthcare · Medical Instruments & Supplies
Desk view
Market read
POC $164.20 · VWAP $146.39 · +20.9% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
1 related campaign
RGEN Price Structure
Loading timeframes…
Peers
Every watchlist RGEN belongs to, members best 30-day change first — RGEN highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
Reported the quarter ending 2026-06-30: revenue $204M, diluted EPS $0.09, net income $5M (SEC filing). Across the print the stock moved +7.8% (close before → first close after).
full note →Against street estimates
How RGEN's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
Recent news
Headlines about RGEN from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled today · Oct 23
- Repligen (RGEN) — Company Dossier — Palanor
- Barclays Sticks to Its Buy Rating for Repligen (RGEN) | Markets Insider
- Repligen Corporation - Repligen Completes Acquisition of BioLife Solutions
- Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance - BioSpace
- REPLIGEN CORP 8-K exhibit 99.1, filed July 22, 2026
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
RGEN research tape
37 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.